---
company: NEOGENOMICS INC
ticker: NEO
form: 8-K
filed: 2026-07-28
accession: 0001077183-26-000058
source: https://www.sec.gov/Archives/edgar/data/1077183/000107718326000058/
---

# Neogenomics (NEO) earnings release, July 28, 2026

Neogenomics Inc (NEO) · Form 8-K, Item 2.02 · Filed 2026-07-28 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1077183/000107718326000058/)

NeoGenomics Reports Second Quarter 2026 Results

Total revenue increased 11% YoY to $202 million

Clinical services revenue grew 14%, with NGS revenue growth of 26%

Company raises full-year 2026 revenue and adjusted EBITDA guidance

Fort Myers, Florida (July 28, 2026) - NeoGenomics, Inc. (NASDAQ: NEO) (the

“

Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its second-quarter results for the period ended June 30, 2026.

“Our second quarter results reflect the consistent operating and financial performance investors expect from this team,” said Tony Zook, Chief Executive Officer of NeoGenomics. “Revenue growth of 11% year-over-year exceeded our outlook, with NGS revenue growth of 26% reflecting a continued mix shift to more advanced testing modalities. This revenue growth is being coupled with our focus on disciplined margin expansion, as evidenced by adjusted EBITDA increasing by 36%. Looking ahead, I remain confident that we are well positioned to deliver long-term profitable growth, while investing in our business and expanding our suite of on-market testing solutions for patients and providers.”

Second-Quarter Results

Consolidated revenue for the second quarter of 2026 was $202 million, an increase of 11% over the same period in 2025. Clinical volume increased by 2%, while average revenue per clinical test increased by 12% to $515.

Consolidated gross profit for the second quarter of 2026 was $92 million, an increase of 19% compared to the second quarter of 2025. Consolidated gross profit margin, including amortization of acquired intangible assets and stock-based

NeoGenomics, Inc. | 9490 NeoGenomics Way Fort Myers, FL 33912

Page

|

2 compensation expense, was 46%. Adjusted Gross Profit Margin

(1), excluding amortization of acquired intangible assets and stock-based compensation expense, was 48%, an increase of 260 bps versus the same period in 2025.

Operating expenses for the second quarter of 2026 were $102 million, a decrease of $23 million, or 19%, compared to the second quarter of 2025. The decrease in operating expenses was primarily due to $20 million of impairment charges taken in the second quarter of 2025.

Net income for the quarter was $2 million compared to net loss of $45 million for the second quarter of 2025. Net income for the quarter includes a gain on extinguishment of debt of $11 million.

Adjusted EBITDA

(1) for the second quarter of 2026 increased by 36% to $14 million, compared to $11 million in the second quarter of 2025. Adjusted Net Income

(1) was $7 million compared to Adjusted Net Income

(1) of $4 million in the second quarter of 2025.

Cash and cash equivalents totaled $146 million at quarter end. This reflects the net effects from the completion of the company’s $316 million private offering of 0.75% convertible senior notes due 2032. As part of the transaction, the Company repurchased approximately $276 million aggregate principal amount of the Company’s existing 0.25% convertible senior notes due 2028 and entry into capped call transactions intended to reduce potential dilution upon conversion. Company also repurchased shares of its common stock for an aggregate purchase price of $25 million.

(1)

The Company has provided adjusted financial information that has not been prepared in accordance with GAAP, including Adjusted EBITDA, Adjusted Gross Profit Margin, Adjusted Net (Loss) Income, and Adjusted Diluted EPS. Each of these measures is defined in the section of this press release entitled “Use of Non-GAAP Financial Measures.” See also the tables reconciling such measures to their closest GAAP equivalent.

2026 Financial Guidance

The Company is revising its full-year 2026 guidance, as shown below (in millions).

Conference Call

The Company has scheduled a webcast and conference call to discuss its second quarter 2026 results on Tuesday,

July 28, 2026 at 4:30 p.m. Eastern Time. To access the live call via telephone, interested investors should dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to the call. The participant access code provided for this call is 968605. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company’s website.

About NeoGenomics, Inc.

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.

We routinely post information that may be important to investors on our website at https://www.neogenomics.com. Information on, or accessible through, our website is not incorporated by reference into, and is not a part of, this release or any other report or document that we may file with the Securities and Exchange Commission (“SEC”).

NeoGenomics, Inc. | 9490 NeoGenomics Way Fort Myers, FL 33912

Page

|

2

Forward Looking Statements... (truncated) forward-looking statements include statements regarding the Company’s strategy, planned future operations and related expectations with respect to timing and performance, capital structure and future financial position, future operating and financial performance, growth potential and expected growth drivers, projected costs and capital expenditures, prospects and plans, and estimates of market size and position, as well as statements regarding the objectives of management. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company's ability to identify and implement appropriate financial and operational initiatives to execute on its strategic priorities, to enter new markets and increase market share in both current and new markets, to continue gaining new customers, develop and commercialize new types of tests, manage the effects of seasonality, execute on its long-range strategic priorities and otherwise implement its business plans, as well as the potential impact of evolving regulatory requirements related to laboratory developed tests, the impact of tariffs and trade policy uncertainty on the Company's supply chain and costs, and any potential reimbursement changes by the government and commercial payors, and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 and filed with the SEC on February 17, 2026, as well as subsequently filed Quarterly Reports on Form 10-Q and the Company's other filings with the SEC.

We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Investor Contact

InvestorRelations@neogenomics.com

Media Contact

Andrea Sampson asampson@sampsonprgroup.com

NeoGenomics, Inc. | 9490 NeoGenomics Way Fort Myers, FL 33912

Page

|

3

## Financial statements

### Income Statement (Previous FY 2026 Guidance — The Company is revising its full-year 2026 guidance, as shown below (in millions).)

| | FY 2025 – Actual | Previous FY 2026 Guidance – Low | Previous FY 2026 Guidance – High | Updated FY 2026 Guidance – Low | Updated FY 2026 Guidance – High | YOY % Change from FY 2025 – Low | YOY % Change from FY 2025 – High |
|---|---:|---:|---:|---:|---:|---:|---:|
| Consolidated revenue | 727 | 797 | 803 | 802 | 806 | 10.0% | 11.0% |
| Net loss | -108 | -63 | -50 | -42 | -34 | 61.0% | 69.0% |
| Adjusted EBITDA | 43 | 55 | 57 | 56 | 58 | 29.0% | 34.0% |

### Income Statement (Three Months Ended June 30, — (unaudited))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| NET REVENUE | 201,656 | 181,330 | 388,328 | 349,365 |
| COST OF REVENUE | 109,778 | 104,072 | 215,586 | 198,861 |
| GROSS PROFIT | 91,878 | 77,258 | 172,742 | 150,504 |
| Operating expenses: | General and administrative | 63,613 | 71,747 | 129,354 | 139,954 |
| Operating expenses: | Research and development | 10,761 | 9,023 | 20,295 | 19,204 |
| Operating expenses: | Sales and marketing | 27,275 | 24,075 | 51,105 | 46,758 |
| Operating expenses: | Impairment charges |  | 20,041 |  | 20,041 |
| Operating expenses: | Total operating expenses | 101,649 | 124,886 | 200,754 | 225,957 |
| Operating expenses: | LOSS FROM OPERATIONS | -9,771 | -47,628 | -28,012 | -75,453 |
| Operating expenses: | Interest income | 1,214 | 2,263 | 2,487 | 5,984 |
| Operating expenses: | Interest expense | -781 | -933 | -1,379 | -2,551 |
| Operating expenses: | Other (expense) income, net | -17 | 482 | -29 | 547 |
| Operating expenses: | Gain on extinguishment of debt | 11,181 |  | 11,181 |  |
| Operating expenses: | Income (loss) before taxes | 1,826 | -45,816 | -15,752 | -71,473 |
| Operating expenses: | Income tax benefit | 412 | 724 | 884 | 458 |
| Operating expenses: | NET INCOME (LOSS) | 2,238 | -45,092 | -14,868 | -71,015 |
| NET INCOME (LOSS) PER SHARE | Basic | 0.02 | -0.35 | -0.11 | -0.56 |
| NET INCOME (LOSS) PER SHARE | Diluted | 0.02 | -0.35 | -0.11 | -0.56 |
| WEIGHTED AVERAGE COMMON SHARES OUTSTANDING | Basic | 129,628 | 127,949 | 129,398 | 127,664 |
| WEIGHTED AVERAGE COMMON SHARES OUTSTANDING | Diluted | 130,831 | 127,949 | 129,398 | 127,664 |

### Income Statement (Three Months Ended June 30, — (unaudited))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Net income (loss) (GAAP) | 2,238 | -45,092 | -14,868 | -71,015 |
| Adjustments to net income (loss): | Interest income | -1,214 | -2,263 | -2,487 | -5,984 |
| Adjustments to net income (loss): | Interest expense | 781 | 933 | 1,379 | 2,551 |
| Adjustments to net income (loss): | Income tax benefit | -412 | -724 | -884 | -458 |
| Adjustments to net income (loss): | Depreciation | 8,577 | 9,140 | 17,357 | 18,506 |
| Adjustments to net income (loss): | Amortization | 7,974 | 8,124 | 15,607 | 16,486 |
| Adjustments to net income (loss): | EBITDA (non-GAAP) | 17,944 | -29,882 | 16,104 | -39,914 |
| Further adjustments to EBITDA: | Leadership transition costs(1) | 245 | 637 | 563 | 2,831 |
| Further adjustments to EBITDA: | Acquisition and integration related expenses(2) |  | 3,204 | 806 | 4,376 |
| Further adjustments to EBITDA: | Stock-based compensation expense | 8,216 | 12,215 | 17,852 | 22,968 |
| Further adjustments to EBITDA: | Gain on extinguishment of debt | -11,181 |  | -11,181 |  |
| Further adjustments to EBITDA: | Impairment charges(3) |  | 20,041 |  | 20,041 |
| Further adjustments to EBITDA: | IP litigation costs(4) | 81 | 4,460 | 165 | 7,443 |
| Further adjustments to EBITDA: | Adjustment to contingency for regulatory matter | -1,155 |  | -1,155 |  |
| Further adjustments to EBITDA: | Other significant expenses, net(5) | 317 |  | 317 |  |
| Further adjustments to EBITDA: | Adjusted EBITDA (non-GAAP) | 14,467 | 10,675 | 23,471 | 17,745 |

### Income Statement (Three Months Ended June 30, — (unaudited))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Three Months Ended June 30, – 2025 | Three Months Ended June 30, – % Change | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | Six Months Ended June 30, – 2025 | Six Months Ended June 30, – % Change |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| Consolidated: | Total revenue (GAAP) |  | 201,656 |  | 181,330 | 11.2% |  | 388,328 |  | 349,365 | 11.2% |
| Consolidated: | Cost of revenue (GAAP) |  | 109,778 |  | 104,072 | 5.5% |  | 215,586 |  | 198,861 | 8.4% |
| Consolidated: | Adjustments to cost of revenue(1) | -5,021 |  | -5,114 |  |  | -9,972 |  | -10,439 |  |  |
| Consolidated: | Adjusted cost of revenue (non-GAAP) |  | 104,757 |  | 98,958 | 5.9% |  | 205,614 |  | 188,422 | 9.1% |
| Consolidated: | Gross profit (GAAP) |  | 91,878 |  | 77,258 | 18.9% |  | 172,742 |  | 150,504 | 14.8% |
| Consolidated: | Adjusted gross profit (non-GAAP ) |  | 96,899 |  | 82,372 | 17.6% |  | 182,714 |  | 160,943 | 13.5% |
| Consolidated: | Gross profit margin (GAAP) | 45.6 | % | 42.6 | % |  | 44.5 | % | 43.1 | % |  |
| Consolidated: | Adjusted gross profit margin (non-GAAP) | 48.1 | % | 45.4 | % |  | 47.1 | % | 46.1 | % |  |

### Income Statement (Three Months Ended June 30, — (unaudited))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Net income (loss) (GAAP) | 2,238 | -45,092 | -14,868 | -71,015 |
| Adjustments to net income (loss) net of tax: | Amortization | 7,974 | 8,124 | 15,607 | 16,486 |
| Adjustments to net income (loss) net of tax: | Leadership transition costs(1) | 245 | 637 | 563 | 2,831 |
| Adjustments to net income (loss) net of tax: | Acquisition and integration related expenses(2) |  | 3,204 | 806 | 4,376 |
| Adjustments to net income (loss) net of tax: | Stock-based compensation expense | 8,216 | 12,215 | 17,852 | 22,968 |
| Adjustments to net income (loss) net of tax: | Gain on extinguishment of debt | -11,181 |  | -11,181 |  |

### Income Statement (Year Ended December 31, 2026)

| | Year Ended December 31, 2026 – Low Range | Year Ended December 31, 2026 – High Range |
|---|---:|---:|
| Net loss (GAAP) | -42,000 | -34,000 |
| Amortization | 32,000 | 32,000 |
| Stock-based compensation expenses | 37,000 | 35,000 |
| Other one-time expenses | -5,000 | -7,000 |
| Adjusted net income (non-GAAP) | 22,000 | 26,000 |
| Interest and taxes | -2,000 | -2,000 |
| Depreciation | 36,000 | 34,000 |
| Adjusted EBITDA (non-GAAP) | 56,000 | 58,000 |
| Net loss per diluted share (GAAP) | -0.32 | -0.26 |
| Adjustments to net loss per diluted share: | Amortization | 0.25 | 0.25 |
| Adjustments to net loss per diluted share: | Stock-based compensation expenses | 0.28 | 0.27 |
| Adjustments to net loss per diluted share: | Other one-time expenses | -0.04 | -0.05 |
| Adjustments to net loss per diluted share: | Rounding and impact of diluted shares in adjusted diluted shares(1) |  | -0.01 |
| Adjustments to net loss per diluted share: | Adjusted diluted EPS (non-GAAP) | 0.17 | 0.2 |
| Weighted average assumed shares outstanding in 2026: | Diluted shares (GAAP) | 130,000 | 130,000 |
| Weighted average assumed shares outstanding in 2026: | Adjusted diluted shares outstanding (non-GAAP) | 130,000 | 130,000 |

### Balance Sheet (December 31, 2025 — (in thousands))

| | June 30, 2026 (unaudited) | December 31, 2025 |
|---|---:|---:|
| Current assets | Cash and cash equivalents | 145,539 | 159,618 |
| Current assets | Accounts receivable, net | 175,405 | 159,242 |
| Current assets | Inventories | 27,137 | 28,566 |
| Current assets | Prepaid assets | 23,590 | 21,443 |
| Current assets | Other current assets | 9,807 | 7,417 |
| Current assets | Total current assets | 381,478 | 376,286 |
| Current assets | Property and equipment, net | 80,938 | 84,834 |
| Current assets | Operating lease right-of-use assets | 78,606 | 78,444 |
| Current assets | Financing lease right-of-use assets | 6,653 | 54 |
| Current assets | Intangible assets, net | 271,262 | 286,528 |
| Current assets | Goodwill | 523,995 | 524,344 |
| Current assets | Other assets | 9,311 | 9,340 |
| Current assets | Total non-current assets | 970,765 | 983,544 |
| Current assets | Total assets | 1,352,243 | 1,359,830 |
| Current liabilities | Accounts payable and other current liabilities | 100,457 | 83,496 |
| Current liabilities | Current portion of operating lease liabilities | 3,722 | 4,776 |
| Current liabilities | Current portion of finance lease liabilities | 1,704 | 28 |
| Current liabilities | Total current liabilities | 105,883 | 88,300 |
| Long-term liabilities | Operating lease liabilities | 64,671 | 62,822 |
| Long-term liabilities | Finance lease liabilities | 4,030 | 27 |
| Long-term liabilities | Convertible senior notes, net | 374,241 | 341,858 |
| Long-term liabilities | Deferred income tax liabilities, net | 16,824 | 18,219 |
| Long-term liabilities | Other long-term liabilities | 862 | 12,042 |
| Long-term liabilities | Total long-term liabilities | 460,628 | 434,968 |
| Long-term liabilities | Total liabilities | 566,511 | 523,268 |
| Stockholders’ equity | Total stockholders' equity | 785,732 | 836,562 |
| Stockholders’ equity | Total liabilities and stockholders’ equity | 1,352,243 | 1,359,830 |

### Cash Flow (Six Months Ended June 30, — (unaudited))

| | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|
| CASH FLOWS FROM OPERATING ACTIVITIES | Net loss | -14,868 | -71,015 |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | Depreciation | 17,356 | 18,506 |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | Amortization of intangibles | 15,267 | 16,486 |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | Stock-based compensation | 17,852 | 22,968 |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | Non-cash operating lease expense | 3,226 | 3,346 |
